Burcin Karasah Erkek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Burcin Karasah Erkek has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Burak Akovalı
Department of Nuclear Medicine, Faculty of Medicine, Canakkale Onsekiz Mart University, Canakkale, Türkiye
2 shared publications - Esra Çiftçi
Department of Nuclear Medicine, Sakarya University Faculty of Medicine, Research and Training Hospital, Sakarya, Türkiye
2 shared publications - Hatice Sariyildiz Gumusgoz
Department of Nuclear Medicine, Faculty of Medicine, Sakarya University, Research and Training Hospital, Sakarya, Türkiye
2 shared publications - Ahmet Aydın ÖZSARAN
Ege Üniversitesi Tıp Fakültesi, Jinekolojik Onkoloji Bilim Dalı, İzmir
1 shared publication - Alpay Tunç
Ege University Faculty of Medicine, Department of Nuclear Medicine, İzmir, Türkiye
1 shared publication Burak Turna
Urology, Ege University Medical Faculty, Izmir, Turkey
1 shared publication
Latest Publications
- Open Access
- 4 June 2026
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 35 (2) , 105-113
Potential of Lean Body Mass 18F-FDG PET/CT Parameters to Predict Pathologic Findings in Overweight Endometrial Cancer Cases
Potential of Lean Body Mass 18F-FDG PET/CT Parameters to Predict Pathologic Findings in Overweight Endometrial Cancer Cases - Molecular Imaging and Radionuclide Therapy
- 4 June 2026
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 35 (2) , 105-113
Open AccessPotential of Lean Body Mass 18F-FDG PET/CT Parameters to Predict Pathologic Findings in Overweight Endometrial Cancer Cases
Potential of Lean Body Mass 18F-FDG PET/CT Parameters to Predict Pathologic Findings in Overweight Endometrial Cancer Cases - Molecular Imaging and Radionuclide Therapy
- 20 March 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (suppl2) , 167-171
Investigating the FIB-4 index and PET/CT metabolic parameters for the differentiation status of hepatocellular carcinoma
Aim The FIB-4 index is a widely used noninvasive marker of hepatic fibrosis and has prognostic value in hepatocellular carcinoma (HCC). However, its association with tumor differentiation remains unclear. This study aimed to investigate the relationship between the fibrosis-4 (FIB-4) index and histological differentiation of HCC using 18F- fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters. Methods This retrospective, single-center study included 110 patients with newly diagnosed, histologically confirmed HCC who underwent 18F-FDG PET/CT between 2017 and 2024. Patients with moderately differentiated or unclassified tumors, prior liver-directed therapies, recurrent HCC, or other malignancies were excluded. Tumors were categorized as well-differentiated or poorly-differentiated. PET/CT-derived metabolic parameters were analyzed. The FIB-4 index was calculated at the time of imaging. Group comparisons, correlation analyses, and receiver operating characteristic (ROC) curve analyses were performed to evaluate associations among FIB-4, metabolic parameters, and tumor differentiation. Results The median FIB-4 index did not differ significantly between well- and poorly differentiated HCC groups (4.2 vs. 4.5, p = 0.765). No significant correlation was observed between the FIB-4 index and PET metabolic parameters (all p > 0.05). In contrast, poorly-differentiated HCCs showed significantly higher metabolic activity, with markedly elevated SUVmax, SUVmean, SUVpeak, tumor-to-liver and tumor-to-blood ratios (all p < 0.001). ROC analysis showed that SUVmax had the highest diagnostic performance for predicting poor differentiation (AUC = 0.981), whereas the FIB-4 index had poor discriminative ability (AUC = 0.517). Conclusion The FIB-4 index does not reflect histological differentiation in HCC and has limited utility for tumor grading. 18F-FDG PET/CT metabolic parameters provide superior discrimination of tumor differentiation, although overlap between grades underscores the need for a multimodal diagnostic approach.
- 20 March 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (suppl2) , 167-171
Investigating the FIB-4 index and PET/CT metabolic parameters for the differentiation status of hepatocellular carcinoma
Aim The FIB-4 index is a widely used noninvasive marker of hepatic fibrosis and has prognostic value in hepatocellular carcinoma (HCC). However, its association with tumor differentiation remains unclear. This study aimed to investigate the relationship between the fibrosis-4 (FIB-4) index and histological differentiation of HCC using 18F- fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters. Methods This retrospective, single-center study included 110 patients with newly diagnosed, histologically confirmed HCC who underwent 18F-FDG PET/CT between 2017 and 2024. Patients with moderately differentiated or unclassified tumors, prior liver-directed therapies, recurrent HCC, or other malignancies were excluded. Tumors were categorized as well-differentiated or poorly-differentiated. PET/CT-derived metabolic parameters were analyzed. The FIB-4 index was calculated at the time of imaging. Group comparisons, correlation analyses, and receiver operating characteristic (ROC) curve analyses were performed to evaluate associations among FIB-4, metabolic parameters, and tumor differentiation. Results The median FIB-4 index did not differ significantly between well- and poorly differentiated HCC groups (4.2 vs. 4.5, p = 0.765). No significant correlation was observed between the FIB-4 index and PET metabolic parameters (all p > 0.05). In contrast, poorly-differentiated HCCs showed significantly higher metabolic activity, with markedly elevated SUVmax, SUVmean, SUVpeak, tumor-to-liver and tumor-to-blood ratios (all p < 0.001). ROC analysis showed that SUVmax had the highest diagnostic performance for predicting poor differentiation (AUC = 0.981), whereas the FIB-4 index had poor discriminative ability (AUC = 0.517). Conclusion The FIB-4 index does not reflect histological differentiation in HCC and has limited utility for tumor grading. 18F-FDG PET/CT metabolic parameters provide superior discrimination of tumor differentiation, although overlap between grades underscores the need for a multimodal diagnostic approach.
- Open Access
- 3 March 2026
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 40 (7) , 746-753
Predictive value of the 68Ga-PSMA-11 PET/CT PRIMARY score for pathological upgrading in patients with ISUP Grade 1 prostate cancer and PSA < 20 ng/mL undergoing radical prostatectomy
Objective: Pathological upgrading is common in men with ISUP Grade Group (GG) 1 prostate cancer due to sampling limitations. 68 Ga-PSMA-11 PET/CT is promising for characterizing tumor biology. The 5-point PRIMARY score, which considers uptake, focality, and location, has limited data on predicting occult high-grade cancer in GG1 biopsy patients. This study assessed the score’s accuracy in predicting upgrading in GG1 prostate cancer patients with PSA < 20 ng/mL undergoing radical prostatectomy. Materials and methods: This retrospective study included 71 patients with biopsy-proven GG1 prostate adenocarcinoma, PSA < 20 ng/mL, and 68 Ga-PSMA-11 PET/CT performed within 2 months before radical prostatectomy. PRIMARY scores [1–5] were assigned by two blinded nuclear medicine physicians; scores ≥ 4 were considered high-risk. Pathological upgrading was defined as ISUP GG ≥ 2 on prostatectomy specimens. Diagnostic performance was assessed using ROC analysis, and univariate and multivariate logistic regression models were constructed to determine independent predictors of upgrading. Results: Pathological upgrading occurred in 45/71 patients (63.4%). Upgrading rates increased markedly across PRIMARY score categories: 25% for scores ≤ 3, 81.3% for score 4, and 100% for score 5 ( p < 0.001). A PRIMARY score ≥ 4 demonstrated excellent diagnostic performance (AUC = 0.979), with 97.8% sensitivity, 88.5% specificity, 93.6% PPV, 95.6% NPV, and 94.3% accuracy. SUVmax (AUC = 0.944) and PI-RADS ≥ 4 (AUC = 0.721) were also associated with upgrading; however, in multivariate analysis, only the PRIMARY score remained an independent predictor (OR: 19.9; 95% CI: 2.92-135.28; p = 0.002). Conclusion: “The 68 Ga-PSMA-11 PET/CT PRIMARY score was strongly associated with pathological upgrading in this surgically treated cohort of biopsy-confirmed ISUP GG1 patients with PSA < 20 ng/mL undergoing radical prostatectomy. Incorporating PSMA-based intraprostatic pattern analysis could improve the accuracy of preoperative grading, potentially supporting consideration of surgical management rather than definitive radiotherapy when determining the optimal treatment strategy. Prospective multicenter validation is warranted before broader clinical implementation.
- 3 March 2026
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 40 (7) , 746-753
Open AccessPredictive value of the 68Ga-PSMA-11 PET/CT PRIMARY score for pathological upgrading in patients with ISUP Grade 1 prostate cancer and PSA < 20 ng/mL undergoing radical prostatectomy
Objective: Pathological upgrading is common in men with ISUP Grade Group (GG) 1 prostate cancer due to sampling limitations. 68 Ga-PSMA-11 PET/CT is promising for characterizing tumor biology. The 5-point PRIMARY score, which considers uptake, focality, and location, has limited data on predicting occult high-grade cancer in GG1 biopsy patients. This study assessed the score’s accuracy in predicting upgrading in GG1 prostate cancer patients with PSA < 20 ng/mL undergoing radical prostatectomy. Materials and methods: This retrospective study included 71 patients with biopsy-proven GG1 prostate adenocarcinoma, PSA < 20 ng/mL, and 68 Ga-PSMA-11 PET/CT performed within 2 months before radical prostatectomy. PRIMARY scores [1–5] were assigned by two blinded nuclear medicine physicians; scores ≥ 4 were considered high-risk. Pathological upgrading was defined as ISUP GG ≥ 2 on prostatectomy specimens. Diagnostic performance was assessed using ROC analysis, and univariate and multivariate logistic regression models were constructed to determine independent predictors of upgrading. Results: Pathological upgrading occurred in 45/71 patients (63.4%). Upgrading rates increased markedly across PRIMARY score categories: 25% for scores ≤ 3, 81.3% for score 4, and 100% for score 5 ( p < 0.001). A PRIMARY score ≥ 4 demonstrated excellent diagnostic performance (AUC = 0.979), with 97.8% sensitivity, 88.5% specificity, 93.6% PPV, 95.6% NPV, and 94.3% accuracy. SUVmax (AUC = 0.944) and PI-RADS ≥ 4 (AUC = 0.721) were also associated with upgrading; however, in multivariate analysis, only the PRIMARY score remained an independent predictor (OR: 19.9; 95% CI: 2.92-135.28; p = 0.002). Conclusion: “The 68 Ga-PSMA-11 PET/CT PRIMARY score was strongly associated with pathological upgrading in this surgically treated cohort of biopsy-confirmed ISUP GG1 patients with PSA < 20 ng/mL undergoing radical prostatectomy. Incorporating PSMA-based intraprostatic pattern analysis could improve the accuracy of preoperative grading, potentially supporting consideration of surgical management rather than definitive radiotherapy when determining the optimal treatment strategy. Prospective multicenter validation is warranted before broader clinical implementation.
- 21 October 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (6) , 3510-3512
A rare case: solitary fibrous tumor with widespread metastasis on [68Ga]Ga-DOTATATE PET/CT
Background Intracranial solitary fibrous tumor (SFT) are rare pericyte neoplasms arising from the meninges. They resemble meningiomas due to their location and are hyperdense on CT. Therefore, they may be a source of pitfalls. However, unlike meningiomas, there is no calcification or hyperostosis of the adjacent bone. We report a rare case of metastatic SFT presenting with masses in the left cerebral hemisphere, both lungs, left kidney, C4 vertebra, and scalp with intense radiotracer uptake. Case presentation A 66-year-old male patient was referred to our center with intracranial masses initially diagnosed as meningiomas. The patient, who developed compression symptoms, underwent surgery for masses in the left cerebral hemisphere. According to WHO classification [1], the pathology revealed as high-risk (grade 3) SFT with high proliferative activity. Immunohistochemical findings: Bcl-2—124 (positive), CD34 (focal pale positive), CD99 (membranous positive), Ki67 (MIB1): %14, PHH3 (positive in 10 cells in per 10 high-power fields), STAT 6 (diffuse nuclear positive). And 10 mitoses were seen in per 10 high-power fields. Imaging results revealed extracranial metastases in addition to intracranial masses, both demonstrating intense radiotracer uptake. Conclusions Although SFTs can be confused with meningiomas based on imaging findings, distinguishing between the two is crucial due to the rarity, aggressive behavior, and potential for extracranial metastasis associated with SFTs. Ga-68 DOTA PET/CT offers significant contributions to the differential diagnosis of these two tumor types. However, it is known in the literature that meningiomas can also exhibit a high rate of DOTA uptake, and, although rare, extracranial metastases can exhibit DOTA positivity. Therefore, a holistic approach to evaluating radiologic, clinical, and histopathologic findings is necessary for definitive diagnosis, rather than relying solely on Ga-68 DOTA PET/CT findings. Furthermore, as seen in this rare case with limited therapeutic options, the high expression of somatostatin receptor raises the possibility of radiolabeled somatostatin analogs as a potential treatment option in the context of widespread metastatic disease.
- 21 October 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (6) , 3510-3512
A rare case: solitary fibrous tumor with widespread metastasis on [68Ga]Ga-DOTATATE PET/CT
Background Intracranial solitary fibrous tumor (SFT) are rare pericyte neoplasms arising from the meninges. They resemble meningiomas due to their location and are hyperdense on CT. Therefore, they may be a source of pitfalls. However, unlike meningiomas, there is no calcification or hyperostosis of the adjacent bone. We report a rare case of metastatic SFT presenting with masses in the left cerebral hemisphere, both lungs, left kidney, C4 vertebra, and scalp with intense radiotracer uptake. Case presentation A 66-year-old male patient was referred to our center with intracranial masses initially diagnosed as meningiomas. The patient, who developed compression symptoms, underwent surgery for masses in the left cerebral hemisphere. According to WHO classification [1], the pathology revealed as high-risk (grade 3) SFT with high proliferative activity. Immunohistochemical findings: Bcl-2—124 (positive), CD34 (focal pale positive), CD99 (membranous positive), Ki67 (MIB1): %14, PHH3 (positive in 10 cells in per 10 high-power fields), STAT 6 (diffuse nuclear positive). And 10 mitoses were seen in per 10 high-power fields. Imaging results revealed extracranial metastases in addition to intracranial masses, both demonstrating intense radiotracer uptake. Conclusions Although SFTs can be confused with meningiomas based on imaging findings, distinguishing between the two is crucial due to the rarity, aggressive behavior, and potential for extracranial metastasis associated with SFTs. Ga-68 DOTA PET/CT offers significant contributions to the differential diagnosis of these two tumor types. However, it is known in the literature that meningiomas can also exhibit a high rate of DOTA uptake, and, although rare, extracranial metastases can exhibit DOTA positivity. Therefore, a holistic approach to evaluating radiologic, clinical, and histopathologic findings is necessary for definitive diagnosis, rather than relying solely on Ga-68 DOTA PET/CT findings. Furthermore, as seen in this rare case with limited therapeutic options, the high expression of somatostatin receptor raises the possibility of radiolabeled somatostatin analogs as a potential treatment option in the context of widespread metastatic disease.
- 12 May 2021
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47 (1) , e17-e19
COVID-19 Lung Findings Detected by 68Ga-PSMA PET/CT for Staging Purposes in Patients With Prostate Cancer
We report 3 patients with COVID-19 findings in 68Ga-PSMA PET/CT taken for staging. The first patient, A 64-year-old man with prostate cancer, who had COVID-19 in November 2020 and whose treatment was completed, was observed to continue with COVID-19 findings in 68Ga-PSMA PET/CT in December 2020 before surgery. Other patients were asymptomatic for the disease. It was determined that a PSMA uptake in the lungs corresponding to the CT findings of COVID-19 had increased in 68Ga-PSMA PET/CT.
- 12 May 2021
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47 (1) , e17-e19
COVID-19 Lung Findings Detected by 68Ga-PSMA PET/CT for Staging Purposes in Patients With Prostate Cancer
We report 3 patients with COVID-19 findings in 68Ga-PSMA PET/CT taken for staging. The first patient, A 64-year-old man with prostate cancer, who had COVID-19 in November 2020 and whose treatment was completed, was observed to continue with COVID-19 findings in 68Ga-PSMA PET/CT in December 2020 before surgery. Other patients were asymptomatic for the disease. It was determined that a PSMA uptake in the lungs corresponding to the CT findings of COVID-19 had increased in 68Ga-PSMA PET/CT.